Finance

Lists
Why is KPTI down ७.४५%?
Dive Deeper
KPTI:NASDAQ
Karyopharm Therapeutics Inc
US$ ०.८०
-७.४५%
(-०.०६५) 1D
US$ ०.८०
०.००% (०.००)
After hours
Closed: अक्टोबर २, १६:००:०० GMT-४  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for KPTI...
Open
US$ ०.८६
High
US$ ०.८९
Low
US$ ०.७५
Mkt. cap
१.८१ करोड
Avg. vol.
१३.६६ लाख
Volume
२३.३५ लाख
52-wk high
US$ १०.९९
52-wk low
US$ ०.७५
EPS
-US$ १२.८४
Beta
१.०४
Shares outstanding
२.२७ करोड
No. of employees
२२८
Open
US$ ०.८६
High
US$ ०.८९
Low
US$ ०.७५
Mkt. cap
१.८१ करोड
Avg. vol.
१३.६६ लाख
Volume
२३.३५ लाख
52-wk high
US$ १०.९९
52-wk low
US$ ०.७५
EPS
-US$ १२.८४
Beta
१.०४
Shares outstanding
२.२७ करोड
No. of employees
२२८
News stories
From web sources and news partners
About Karyopharm Therapeutics Inc
CEO-
Employees२२८
Founded२००८
HeadquartersNewton, म्यासेचुसेट्स, संयुक्त राज्य अमेरिका
Sector-
Analyst ratings
Based on 6 analysts giving stock ratings to KPTI in the past 3 months
Buy
Buy
4
Hold
2
Sell
0
12-month forecast
Based on 6 Wall Street analysts offering 12 month price targets for KPTI in the last 3 months.
Highest
Current US$ ०.८०
US$ ११.०० (+१,२७१.२३%)
Average
US$ ६.५४ (+७१५.२६%)
Lowest
US$ ३.०० (+२७३.९७%)
Analyst
Recommendation
Action
Price target
Projected
Date
Yanni Souroutzidis
Cantor Fitzgerald
Buy
Maintained
US$ ३.६८
+३५८.७%
09/01/2026
Brian Abrahams
RBC Capital
Buy
Maintained
US$ ८.००
+८९७.३%
08/13/2026
Maury Raycroft
Jefferies
Buy
Maintained
US$ ११.००
+१,२७१.२%
07/31/2026
Colleen M. Kusy
Robert W. Baird
Hold
Downgraded
-
-
07/31/2026
Edward Tenthoff
Piper Sandler
Buy
Maintained
US$ ७.००
+७७२.६%
07/31/2026
Robert Burns
H.C. Wainwright
Hold
Downgraded
US$ ३.००
+२७४%
07/31/2026
Unknown Analyst
Leerink Partners
Hold
Reiterated
US$ ७.००
+७७२.६%
05/15/2026
Michael King
Rodman & Renshaw
Buy
Initiated
US$ २८.००
+३,३९०.४%
03/09/2026
Last report
२०२६ अगस्ट १३
Fiscal period
Q2 2026
EPS / Est. (USD)
-US$ २.३२ / -US$ १.३९
-६६.९१%miss
Revenue / Est. (USD)
३.३४ करोड / ३.२२ करोड
+३.८५%beat
Fiscal Q2 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
२०२५ सेप्टेम्बर
२०२५ डिसेम्बर
२०२६ मार्च
२०२६ जुन
Revenue
४.४० करोड
३.४१ करोड
३.५१ करोड
३.३४ करोड
Cost of goods sold
३.२७ करोड
-९.६५ करोड
३.५१ करोड
३.०० करोड
Cost of revenue
३.२७ करोड
-९.६५ करोड
३.५१ करोड
३.०० करोड
Research and development expenses
-
१२.५६ करोड
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
२.६६ करोड
२.२८ करोड
२.६७ करोड
२.५९ करोड
Operating expense
२.६६ करोड
१४.८४ करोड
२.६७ करोड
२.५९ करोड
Total operating expenses
५.९३ करोड
५.१९ करोड
६.१८ करोड
५.६० करोड
Operating income
-१.५२ करोड
-१.७८ करोड
-२.६८ करोड
-२.२५ करोड
Other non operating income
-७४.१८ लाख
-१.०० करोड
१.६४ करोड
-३.२१ करोड
EBT including unusual items
-३.३१ करोड
-१०.२३ करोड
-२.२४ करोड
-६.७० करोड
EBT excluding unusual items
-३.३१ करोड
-३.९९ करोड
-२.२४ करोड
-६.७० करोड
Income tax expense
३४.०० हजार
-६७.०० हजार
१.०० हजार
-
Effective tax rate
-०.१०%
०.०७%
-
-
Other operating expenses
-
-
-
-
Net income
-३.३१ करोड
-१०.२२ करोड
-२.२४ करोड
-६.७० करोड
Net profit margin
-७५.२१%
-२९९.८९%
-६३.८६%
-२००.४८%
Earnings per share
-३.८२
-२.२३
-१.२४
-२.३२
Interest and investment income
५.५३ लाख
६.०७ लाख
५.११ लाख
७.२२ लाख
Interest expense
-१.१० करोड
-१.२६ करोड
-१.२६ करोड
-१.३१ करोड
Net interest expenses
-१.०५ करोड
-१.२० करोड
-१.२० करोड
-१.२४ करोड
Depreciation and amortization charges
-
-
-
-
EBITDA
-१.५१ करोड
-१.७८ करोड
-२.६७ करोड
-२.२५ करोड
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
Google एपहरू